European Archives - Page 8 of 1440 - European Medical Journal

England Relaunches Women’s Health Strategy Amid “Medical Misogyny”

The UK Government has relaunched the Women’s Health Strategy for England on 14th April 2026, following select committee findings of “medical misogyny” in the NHS.

Tuberculosis Vaccine Trial Shows Limited Overall Protection

A phase 3 trial of two tuberculosis vaccines shows limited overall protection but meaningful efficacy against extrapulmonary disease in selected groups.

Dr Henar Hevia on navy blue background

Dr Henar Hevia talks to data, decision-making and cancer care

Columnist Dr Henar Hevia, J&J Innovative Medicine, explores how oncology’s future hinges on smarter use of data.

England’s Advances Towards Hepatitis C Elimination Targets

England reports progress towards hepatitis C elimination as prevalence falls, with diagnosis gaps and harm reduction challenges remaining.

High-Resolution MRI Improves Brain Imaging Clarity

5.0 T SWI improves brain imaging clarity compared with 3.0 T, enhancing visualisation of cerebral veins and deep grey matter structures in healthy adults.

15 Apr 2026

Entering a New Era in Protection in Haemophilia A

Haemophilia A (HA), defined by factor VIII (FVIII) levels ≤40 IU/dL, is a chronic condition with consequences beyond bleeding…

ischaemic heart disease

Poor Diet Drives Global Ischaemic Heart Disease Burden

New findings from the Global Burden of Disease 2023 analysis showed that dietary risks were responsible for an estimated 4.06 million IHD deaths and 96.84 million disability-adjusted life years in 2023.

Music Matches Benzodiazepines in Reducing Perioperative Anxiety

Researchers have calculated the number needed to treat for music intervention in perioperative anxiety and the result is somewhat comparable to that of benzodiazepines.

socioeconomic diabetes

Low Socioeconomic Status Tied to Lower Rates of Diabetes in China

Low socioeconomic status is, overall, tied to a higher prevalence of hypertension and obesity, but lower odds of diabetes and dyslipidaemia in China.

Novo partners with OpenAI to boost drug development

Novo Nordisk announced on 14 April 2026 a strategic partnership with OpenAI to boost drug development by streamlining manufacturing, supply chains and distribution.